A sensitive LC-MS-MS assay for the determination of lapatinib in human plasma in subjects with end-stage renal disease receiving hemodialysis

• Published in: Journal of chromatography. B, Analytical technologies in the biomedical and life sciences Vol. 1097-1098; pp. 74 - 82
• Main Authors: Kocan, Geralyn P., Huang, Mike (Qingtao), Li, Fumin, Pai, Sudhakar
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier B.V 15.10.2018
• Subjects: drugs; End-stage renal disease; enzyme inhibitors; hemodialysis; Human plasma; humans; isotope labeling; kidney diseases; Lapatinib; LC-MS-MS; liquid chromatography; monitoring; neoplasms; patients; tandem mass spectrometry; tyrosine; End-stage renal disease; Human plasma; Lapatinib; LC-MS-MS

Most bioanalytical methods reported in literature for the quantitation of lapatinib in human plasma are either for lapatinib alone or lapatinib administered along with other tyrosine kinase inhibitors (TKIs) for therapeutic drug monitoring (TDM) in cancer patients. Recently there was a need for the...